CASI Pharmaceuticals Inc. | Ownership
Companies that own CASI Pharmaceuticals Inc.
BlackRock Fund Advisors
2,478,371
2.86%
2,102,342
0%
06/30/2018
The Vanguard Group, Inc.
1,662,451
1.92%
386,318
0%
06/30/2018
Wellington Shields & Co. LLC (Investment Management)
951,064
1.1%
325,946
3.19%
06/30/2018
Wellington Shields Capital Management LLC
855,056
0.99%
64,800
0.96%
06/30/2018
SSgA Funds Management, Inc.
593,163
0.69%
569,534
0%
06/30/2018
Northern Trust Investments, Inc.
532,205
0.62%
458,218
0%
06/30/2018
Geode Capital Management LLC
471,019
0.54%
245,441
0%
06/30/2018
BlackRock Investment Management LLC
160,552
0.19%
154,580
0%
06/30/2018
Morgan Stanley & Co. LLC
145,388
0.17%
51,634
0%
06/30/2018
The California Public Employees Retirement System
136,518
0.16%
0
0%
06/30/2018
| Address |
9620 Medical Center Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.casipharmaceuticals.com |
| Updated |
07/08/2019 |
| CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The firm develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. |
